Genmab A/S (OTCMKTS:GNMSF – Get Free Report) saw a significant increase in short interest during the month of April. As of April 15th, there was short interest totalling 169,700 shares, an increase of 7.3% from the March 31st total of 158,100 shares. Based on an average trading volume of 1,000 shares, the short-interest ratio is presently 169.7 days.
Genmab A/S Stock Performance
GNMSF traded up $2.17 during midday trading on Wednesday, reaching $274.22. 120 shares of the company’s stock were exchanged, compared to its average volume of 688. The business’s 50-day moving average price is $292.15 and its 200 day moving average price is $297.77. Genmab A/S has a 1-year low of $262.00 and a 1-year high of $426.50.
Genmab A/S (OTCMKTS:GNMSF – Get Free Report) last released its earnings results on Wednesday, February 14th. The company reported $3.63 earnings per share (EPS) for the quarter. Genmab A/S had a return on equity of 18.06% and a net margin of 26.50%. The company had revenue of $675.29 million during the quarter.
About Genmab A/S
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.
Featured Stories
- Five stocks we like better than Genmab A/S
- Profitably Trade Stocks at 52-Week Highs
- AMD is Down 35%. Now is the Time to Buy the Dip
- What are earnings reports?
- Amazon Stands Tall: New Highs Are in Sight
- How to Buy Cheap Stocks Step by Step
- Chesapeake Energy Stock is The Energy Play, Earnings Confirm
Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.
